LSNE Appoints New COO - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

LSNE Appoints New COO



Untitled Document

Lyophilization Services of New England (LSNE), a New Hampshire based contract-manufacturing organization, has appointed Shawn Cain as COO, a new position within the company. Cain joined LSNE in 2012 as vice- president of sterile manufacturing. In his new role, Cain will be responsible for overseeing day-to-day operations and ensuring companywide alignment with the corporate goals. Cain will report to Matthew Halvorsen, president and CEO of LSNE. Cain's 28-year career includes experience in the pharmaceutical, biotech, and medical device industries. Cain has held management positions within operations at Organogenesis, Formatech, Arbios Systems, and Becton Dickinson.

Source: LSNE

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here